Company
NeuroScientific Biopharmaceuticals Ltd
ASX:NSB
NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) is developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company’s product portfolio includes EmtinBTM, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma.
5 stories
NeuroScientific Biopharmaceuticals to investigate treatment for post-COVID fibrosis
The company is partnering with The Institute of Respiratory Health and The University of Western Australia to test the effectiveness of EmtinB and other Metallothionein derived peptides as potential therapy for COVID-19 respiratory complica
NeuroScientific Biopharmaceuticals completes $2.4 million strategic placement to AlphaSwiss Partners
The company has received strong commitment for the placement, whose proceeds will be used to finish preclinical safety and toxicology programs in ophthalmology and neurology as well as accelerate the start of a Phase 1 study in patients suf
Hardware & electrical equipment
Technologies in spotlight at TechKnow Invest Roadshow
The technology roadshow will stop by in Sydney on Tuesday, March 19, and in Melbourne on Thursday, March 21.
NeuroScientific Biopharmaceuticals debuts on the ASX after maxed out IPO
Shares are trading at a premium to their 20 cent listing price on day one.